ME02612B - Tenofovir alafenamid hemifumarat - Google Patents
Tenofovir alafenamid hemifumaratInfo
- Publication number
- ME02612B ME02612B MEP-2016-273A MEP2016273A ME02612B ME 02612 B ME02612 B ME 02612B ME P2016273 A MEP2016273 A ME P2016273A ME 02612 B ME02612 B ME 02612B
- Authority
- ME
- Montenegro
- Prior art keywords
- tenofovir alafenamide
- alafenamide hemifumarate
- hemifumarate
- tenofovir
- alafenamide
- Prior art date
Links
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524224P | 2011-08-16 | 2011-08-16 | |
| EP12753867.6A EP2744810B2 (en) | 2011-08-16 | 2012-08-15 | Tenofovir alafenamide hemifumarate |
| PCT/US2012/050920 WO2013025788A1 (en) | 2011-08-16 | 2012-08-15 | Tenofovir alafenamide hemifumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02612B true ME02612B (me) | 2017-06-20 |
Family
ID=46785793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-273A ME02612B (me) | 2011-08-16 | 2012-08-15 | Tenofovir alafenamid hemifumarat |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US8754065B2 (me) |
| EP (3) | EP2744810B2 (me) |
| JP (5) | JP5651275B2 (me) |
| KR (1) | KR101612642B1 (me) |
| CN (2) | CN110343135A (me) |
| AP (1) | AP3639A (me) |
| AR (1) | AR087546A1 (me) |
| AU (1) | AU2012296622C1 (me) |
| BR (1) | BR112014003420B1 (me) |
| CA (1) | CA2845553C (me) |
| CL (1) | CL2014000370A1 (me) |
| CO (1) | CO6880063A2 (me) |
| CR (1) | CR20140072A (me) |
| CY (1) | CY1118385T1 (me) |
| DK (1) | DK2744810T4 (me) |
| EA (1) | EA027768B1 (me) |
| EC (1) | ECSP14013206A (me) |
| ES (1) | ES2608871T5 (me) |
| FI (1) | FI2744810T4 (me) |
| HK (1) | HK1199026A1 (me) |
| HR (1) | HRP20161696T4 (me) |
| HU (1) | HUE031253T2 (me) |
| IL (2) | IL230949A (me) |
| IN (1) | IN2014DN01012A (me) |
| LT (1) | LT2744810T (me) |
| MA (1) | MA35350B1 (me) |
| MD (1) | MD4508C1 (me) |
| ME (1) | ME02612B (me) |
| MX (1) | MX336627B (me) |
| PE (1) | PE20141328A1 (me) |
| PL (1) | PL2744810T5 (me) |
| PT (1) | PT2744810T (me) |
| RS (1) | RS55353B2 (me) |
| SG (1) | SG2014011548A (me) |
| SI (1) | SI2744810T2 (me) |
| SM (1) | SMT201600476B (me) |
| TW (1) | TWI516499B (me) |
| UA (1) | UA115311C2 (me) |
| UY (1) | UY34262A (me) |
| WO (1) | WO2013025788A1 (me) |
| ZA (1) | ZA201400582B (me) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34262A (es) | 2011-08-16 | 2013-04-05 | Gilead Sciences Inc | Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos |
| MX353064B (es) | 2011-10-07 | 2017-12-19 | Gilead Sciences Inc | Metodos para preparar analogos nucleotidicos antivirales. |
| CN104105484A (zh) * | 2012-02-03 | 2014-10-15 | 吉联亚科学公司 | 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法 |
| WO2015040640A2 (en) * | 2013-09-20 | 2015-03-26 | Laurus Labs Private Limited | An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof |
| TWI660965B (zh) * | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| US9463194B2 (en) | 2014-02-05 | 2016-10-11 | Gilead Sciences, Inc. | Methods of treating patients co-infected with HIV and tuberculosis |
| CN105085571A (zh) * | 2014-05-20 | 2015-11-25 | 四川海思科制药有限公司 | 替诺福韦艾拉酚胺复合物及其制备方法和用途 |
| CN108191913A (zh) * | 2014-11-12 | 2018-06-22 | 四川海思科制药有限公司 | 一种替诺福韦艾拉酚胺晶型a及其制备方法 |
| CN105237571B (zh) * | 2014-11-28 | 2018-03-09 | 成都苑东生物制药股份有限公司 | 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐 |
| CN104558036A (zh) * | 2014-12-11 | 2015-04-29 | 杭州和泽医药科技有限公司 | 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法 |
| RS62434B1 (sr) | 2014-12-26 | 2021-11-30 | Univ Emory | Antivirusni n4-hidroksicitidin derivati |
| AU2015373104B2 (en) * | 2015-01-03 | 2020-07-09 | Mylan Laboratories Limited | Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof |
| CN105669751B (zh) * | 2015-03-05 | 2018-09-21 | 洛阳聚慧医药科技有限公司 | 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用 |
| GB201509431D0 (en) * | 2015-06-01 | 2015-07-15 | Equigerminal Sa | Antiviral composition |
| CZ2015384A3 (cs) | 2015-06-05 | 2016-12-14 | Zentiva, K.S. | Pevné formy Tenofovir alafenamidu |
| EP4092037A1 (en) | 2015-06-17 | 2022-11-23 | Gilead Sciences, Inc. | Co-crystals, salts and solid forms of tenofovir alafenamide |
| PT4070788T (pt) | 2015-06-30 | 2023-06-06 | Gilead Sciences Inc | Formulações farmacêuticas |
| WO2017007701A1 (en) * | 2015-07-07 | 2017-01-12 | Merck Sharp & Dohme Corp. | Antiviral phosphodiamide compounds |
| WO2017027434A1 (en) | 2015-08-10 | 2017-02-16 | Merck Sharp & Dohme Corp. | Antiviral beta-amino acid ester phosphodiamide compounds |
| WO2017037608A1 (en) * | 2015-08-28 | 2017-03-09 | Laurus Labs Private Limited | Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof |
| JP6621933B2 (ja) | 2015-11-09 | 2019-12-18 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスを処置するための治療組成物 |
| CN106699812A (zh) * | 2015-11-12 | 2017-05-24 | 江苏豪森药业集团有限公司 | 替诺福韦前药的制备和纯化方法 |
| EP3386512B1 (en) | 2015-12-10 | 2023-11-22 | Merck Sharp & Dohme LLC | Antiviral phosphodiamide prodrugs of tenofovir |
| US10450335B2 (en) | 2015-12-15 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| PT3411378T (pt) | 2016-02-02 | 2020-07-28 | Sandoz Ag | Formas cristalinas de monofumarato de tenofovir alafenamida |
| CN107226826A (zh) * | 2016-03-25 | 2017-10-03 | 江苏奥赛康药业股份有限公司 | 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物 |
| WO2017203395A1 (en) * | 2016-05-21 | 2017-11-30 | Shilpa Medicare Limited | Crystalline forms of tenofovir alafenamide hemi fumarate |
| CN109476689B (zh) | 2016-06-05 | 2021-09-03 | 上海诚妙医药科技有限公司 | 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途 |
| PL3597646T3 (pl) | 2016-08-19 | 2023-12-11 | Gilead Sciences, Inc. | Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV |
| EP3503895B1 (en) | 2016-08-25 | 2021-09-15 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
| CN107793451A (zh) * | 2016-08-30 | 2018-03-13 | 江苏奥赛康药业股份有限公司 | 替诺福韦艾拉酚胺半富马酸盐化合物及其药物组合物 |
| WO2018044822A1 (en) * | 2016-08-31 | 2018-03-08 | Viiv Healthcare Company | Combinations and uses and treatments thereof |
| WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
| US10736908B2 (en) | 2016-10-26 | 2020-08-11 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
| CN113072583A (zh) * | 2016-11-28 | 2021-07-06 | 正大天晴药业集团股份有限公司 | 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法 |
| CN108129514A (zh) * | 2016-12-01 | 2018-06-08 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物的单一异构体及其医药用途 |
| CN108070003A (zh) * | 2016-12-02 | 2018-05-25 | 上海博志研新药物技术有限公司 | 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用 |
| RU2759902C2 (ru) | 2016-12-22 | 2021-11-18 | Мерк Шарп И Доум Корп. | Антивирусные алифатические сложноэфирные пролекарства тенофовира |
| WO2018118826A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antiviral benzyl-amine phosphodiamide compounds |
| WO2018113652A1 (zh) | 2016-12-23 | 2018-06-28 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酸类化合物及其制备方法和用途 |
| WO2018115046A1 (en) | 2016-12-23 | 2018-06-28 | Sandoz Ag | Crystalline solid forms of tenofovir alafenamide |
| TWI820984B (zh) * | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| WO2018153977A1 (en) | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
| RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
| CN108794530A (zh) * | 2017-04-26 | 2018-11-13 | 上海医药工业研究院 | 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途 |
| CN107445994A (zh) * | 2017-05-31 | 2017-12-08 | 北京阜康仁生物制药科技有限公司 | 替诺福韦艾拉酚胺半富马酸盐新晶型 |
| RU2662160C9 (ru) | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| CN107522743A (zh) * | 2017-09-30 | 2017-12-29 | 深圳科兴生物工程有限公司 | 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法 |
| CN107865874A (zh) * | 2017-10-23 | 2018-04-03 | 上海博悦生物科技有限公司 | 一种替诺福韦艾拉酚胺的药物组合物及其制备方法 |
| US20190151307A1 (en) | 2017-10-24 | 2019-05-23 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| WO2019130354A1 (en) | 2017-12-30 | 2019-07-04 | Cipla Limited | Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| CA3175384A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
| CN108440596B (zh) * | 2018-03-22 | 2020-07-03 | 科兴生物制药股份有限公司 | 一种半富马酸替诺福韦艾拉酚胺的新型制备工艺 |
| CN111989335B (zh) | 2018-06-12 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途 |
| CN112423750A (zh) | 2018-07-16 | 2021-02-26 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| US11826375B2 (en) | 2018-07-19 | 2023-11-28 | Merck Sharp & Dohme Llc | Phosphinic amide prodrugs of tenofovir |
| CN112996517A (zh) | 2018-09-19 | 2021-06-18 | 吉利德科学公司 | 预防hiv的整合酶抑制剂 |
| KR102054104B1 (ko) * | 2019-04-30 | 2019-12-09 | 유니셀랩 주식회사 | 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| CN110452268A (zh) * | 2019-08-21 | 2019-11-15 | 天地恒一制药股份有限公司 | 一种丙酚替诺福韦半富马酸单晶的制备方法 |
| EP4065116A1 (en) | 2019-11-26 | 2022-10-05 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| WO2021165995A1 (en) * | 2020-02-20 | 2021-08-26 | Cipla Limited | Novel salts and/or co-crystals of tenofovir alafenamide |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| KR20210125298A (ko) | 2020-04-08 | 2021-10-18 | 주식회사 파마코스텍 | 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법 |
| WO2021262990A1 (en) | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| EP4244396A1 (en) | 2020-11-11 | 2023-09-20 | Gilead Sciences, Inc. | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
| US11667656B2 (en) | 2021-01-27 | 2023-06-06 | Apotex Inc. | Crystalline forms of Tenofovir alafenamide |
| KR20220141457A (ko) | 2021-04-13 | 2022-10-20 | 경동제약 주식회사 | 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물 |
| CN118355020A (zh) | 2021-12-03 | 2024-07-16 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
| TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於ｈｉｖ病毒感染之治療性化合物 |
| IL312718A (en) | 2021-12-03 | 2024-07-01 | Gilead Sciences Inc | Therapeutic compounds for HIV infection |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202402280A (zh) | 2022-07-01 | 2024-01-16 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302585A (en) * | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5468768A (en) | 1994-01-06 | 1995-11-21 | Bristol-Myers Squibb Company | Antimigraine derivatives of indolylcycloalkanylamines |
| DK0915894T3 (da) | 1996-07-26 | 2003-09-15 | Gilead Sciences Inc | Nukleotidanaloger |
| CA2261619C (en) | 1996-07-26 | 2006-05-23 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| ATE288914T1 (de) | 1997-07-25 | 2005-02-15 | Gilead Sciences Inc | Nukleotid-analog zusamensetzung und synthese verfahren |
| CN1291994C (zh) | 2000-07-21 | 2006-12-27 | 吉里德科学公司 | 核苷酸膦酸酯类似物前药及其筛选和制备方法 |
| TWI275392B (en) | 2002-04-08 | 2007-03-11 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| JP2004288898A (ja) * | 2003-03-24 | 2004-10-14 | Canon Inc | 太陽電池モジュールの製造方法 |
| ECSP045074A (es) | 2004-04-22 | 2004-05-28 | Inhibidores hidroxipirimidinona carboxamida n-sustituida de integrasa de vih | |
| JP4629104B2 (ja) | 2004-05-21 | 2011-02-09 | 日本たばこ産業株式会社 | ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤 |
| WO2007013086A1 (en) | 2005-07-26 | 2007-02-01 | Hetero Drugs Limited | Novel polymorphs of tenofovir disoproxil fumarate |
| EP2049506B2 (en) | 2006-07-07 | 2024-05-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| ES2532502T3 (es) * | 2006-07-12 | 2015-03-27 | Mylan Laboratories Limited | Proceso para la preparación de tenofovir |
| PT2487163T (pt) | 2007-02-23 | 2016-11-21 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
| WO2008143500A1 (en) * | 2007-05-22 | 2008-11-27 | Ultimorphix Technologies B.V. | Tenofovir disoproxil hemi-fumaric acid co-crystal |
| MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| AU2010210598B2 (en) | 2009-02-06 | 2015-03-05 | Gilead Sciences, Inc. | Tablets for combination therapy |
| US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| CN106511357A (zh) | 2010-11-19 | 2017-03-22 | 吉利德科学公司 | 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物 |
| UY34262A (es) | 2011-08-16 | 2013-04-05 | Gilead Sciences Inc | Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos |
| MX353064B (es) | 2011-10-07 | 2017-12-19 | Gilead Sciences Inc | Metodos para preparar analogos nucleotidicos antivirales. |
| CN104105484A (zh) | 2012-02-03 | 2014-10-15 | 吉联亚科学公司 | 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法 |
-
2012
- 2012-08-15 UY UY0001034262A patent/UY34262A/es active IP Right Grant
- 2012-08-15 UA UAA201401084A patent/UA115311C2/uk unknown
- 2012-08-15 MD MDA20140011A patent/MD4508C1/ro active IP Right Grant
- 2012-08-15 LT LTEP12753867.6T patent/LT2744810T/lt unknown
- 2012-08-15 US US13/586,358 patent/US8754065B2/en active Active
- 2012-08-15 TW TW101129542A patent/TWI516499B/zh active
- 2012-08-15 ES ES12753867T patent/ES2608871T5/es active Active
- 2012-08-15 CN CN201910647566.6A patent/CN110343135A/zh active Pending
- 2012-08-15 CA CA2845553A patent/CA2845553C/en active Active
- 2012-08-15 HR HRP20161696TT patent/HRP20161696T4/hr unknown
- 2012-08-15 MX MX2014001549A patent/MX336627B/es unknown
- 2012-08-15 AR ARP120102988A patent/AR087546A1/es not_active Application Discontinuation
- 2012-08-15 EP EP12753867.6A patent/EP2744810B2/en active Active
- 2012-08-15 WO PCT/US2012/050920 patent/WO2013025788A1/en active Application Filing
- 2012-08-15 SG SG2014011548A patent/SG2014011548A/en unknown
- 2012-08-15 CN CN201280039891.0A patent/CN103732594A/zh active Pending
- 2012-08-15 AP AP2014007437A patent/AP3639A/xx active
- 2012-08-15 HU HUE12753867A patent/HUE031253T2/en unknown
- 2012-08-15 FI FIEP12753867.6T patent/FI2744810T4/fi active
- 2012-08-15 AU AU2012296622A patent/AU2012296622C1/en active Active
- 2012-08-15 KR KR1020147003886A patent/KR101612642B1/ko active Protection Beyond IP Right Term
- 2012-08-15 SI SI201230807T patent/SI2744810T2/sl unknown
- 2012-08-15 EP EP20206486.1A patent/EP3831832A1/en active Pending
- 2012-08-15 EP EP16153076.1A patent/EP3070088A1/en not_active Withdrawn
- 2012-08-15 BR BR112014003420-6A patent/BR112014003420B1/pt active IP Right Grant
- 2012-08-15 PT PT127538676T patent/PT2744810T/pt unknown
- 2012-08-15 EA EA201490208A patent/EA027768B1/ru active Protection Beyond IP Right Term
- 2012-08-15 ME MEP-2016-273A patent/ME02612B/me unknown
- 2012-08-15 DK DK12753867.6T patent/DK2744810T4/da active
- 2012-08-15 PE PE2014000206A patent/PE20141328A1/es active IP Right Grant
- 2012-08-15 JP JP2014526164A patent/JP5651275B2/ja active Active
- 2012-08-15 RS RS20161018A patent/RS55353B2/sr unknown
- 2012-08-15 IN IN1012DEN2014 patent/IN2014DN01012A/en unknown
- 2012-08-15 PL PL12753867.6T patent/PL2744810T5/pl unknown
-
2014
- 2014-01-24 ZA ZA2014/00582A patent/ZA201400582B/en unknown
- 2014-02-12 CO CO14029801A patent/CO6880063A2/es unknown
- 2014-02-12 CR CR20140072A patent/CR20140072A/es unknown
- 2014-02-12 MA MA36754A patent/MA35350B1/fr unknown
- 2014-02-13 CL CL2014000370A patent/CL2014000370A1/es unknown
- 2014-02-13 EC ECSP14013206 patent/ECSP14013206A/es unknown
- 2014-02-13 IL IL230949A patent/IL230949A/en active IP Right Grant
- 2014-03-05 US US14/197,873 patent/US9296769B2/en active Active
- 2014-11-14 JP JP2014231819A patent/JP5956537B2/ja active Active
- 2014-12-11 HK HK14112467.3A patent/HK1199026A1/xx active IP Right Maintenance
-
2015
- 2015-08-18 IL IL240649A patent/IL240649A0/en unknown
-
2016
- 2016-06-16 JP JP2016120153A patent/JP6280162B2/ja active Active
- 2016-12-22 CY CY20161101331T patent/CY1118385T1/el unknown
- 2016-12-28 SM SM201600476T patent/SMT201600476B/it unknown
-
2018
- 2018-01-18 JP JP2018006107A patent/JP2018065870A/ja not_active Withdrawn
-
2019
- 2019-11-21 JP JP2019210196A patent/JP2020040972A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL240649A0 (en) | Tenofovir alafenamide mipomarate | |
| GB201405981D0 (en) | Pallet-dolly | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| EP2679138A4 (en) | Borescope | |
| IL230760A (en) | Polate saccharides are marked in f18 | |
| GB201214881D0 (en) | Abdeckeinrichtung | |
| PL2745011T3 (pl) | Zespół motopompy | |
| HK1198841A1 (en) | Plate-film forming member | |
| AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
| AP00723S1 (en) | Autorickshaw | |
| GB201116059D0 (en) | Project P | |
| AU2011303V (en) | Silverado Dianella tasmanica | |
| GB201102520D0 (en) | Continuous liquid-flow-generator | |
| GB201118343D0 (en) | Toppa-net | |
| GB201113632D0 (en) | P001-10022 | |
| PL395873A1 (pl) | c-papieros | |
| AU338110S (en) | Barstool | |
| GB201112879D0 (en) | FatigueEEG | |
| GB201112523D0 (en) | Mumbrella | |
| GB201112397D0 (en) | Rohypgloss | |
| GB201112272D0 (en) | Nevadrop pickstrap | |
| AU338420S (en) | Kettlebell | |
| GB201110401D0 (en) | BuggyBeams | |
| AP2011000390S (en) | Kuppkraft | |
| GB201106063D0 (en) | Gutterguard |